Federal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Awards Biohaven and Yale University $4 Million

Rhea-AI Summary

Biohaven (NYSE: BHVN) and Yale University announced that a federal jury in the U.S. District Court for the District of Delaware returned a verdict in their favor in trade secret misappropriation and breach of contract litigation against Avilar Therapeutics and RA Capital. The jury found that Avilar and RA Capital willfully and maliciously misappropriated a Yale trade secret related to the MODA targeted protein degradation platform, and that RA Capital separately breached a 2019 confidentiality agreement with Yale. According to Biohaven, the jury awarded a total of $4 million in damages: $2 million to Yale for breach of contract, and $1 million each to Yale and Biohaven for trade secret misappropriation.

Positive

• $4 million damages awarded to Yale and Biohaven by federal jury
• Jury found Yale MODA platform trade secret was misappropriated willfully and maliciously
• RA Capital found to have breached 2019 confidentiality agreement with Yale

Negative

• None.

News Market Reaction – BHVN

+1.33%

20 alerts

+1.33% Session close to close

-2.0% Trough in 2 hr 5 min

$2.07B Market Cap

0.7x Rel. Volume

In the Jul 27 session, BHVN gained 1.33%, reflecting a mild positive market reaction. Argus tracked a trough of -2.0% from its starting point during tracking. Our momentum scanner triggered 20 alerts that day, indicating elevated trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

BHVN's effective S-3ASR shelf dated May 4, 2026 provides financing context for this litigation outco...

Analysis

BHVN's effective S-3ASR shelf dated May 4, 2026 provides financing context for this litigation outcome. Moderate short positioning adds a volatility risk; subsequent filings may clarify treatment of the award and shelf activity.

Key Figures

Combined damages: $4 million Contract damages: $2 million Misappropriation damages: $1 million each +5 more

8 metrics

Combined damages $4 million Federal jury award to Yale and Biohaven

Contract damages $2 million Awarded to Yale for RA Capital's breach of contract

Misappropriation damages $1 million each Awarded to Yale and Biohaven for trade secret misappropriation

Confidentiality agreement April 2019 RA Capital entered into the agreement with Yale

Negotiations ended August 2019 Negotiations between RA Capital and Yale ended without an agreement

Lawsuit filed March 2023 Biohaven and Yale filed suit in Delaware federal court

Jury trial began July 20, 2026 Federal jury trial commencement date

Verdict returned July 24, 2026 Federal jury verdict date

Historical Context

5 past events · Latest: Jul 20 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 20	Clinical data presentation	Positive	-3.8%	New Phase 1 data and Regeneron supply agreement announced ahead of ESMO presentation
Jul 09	Leadership transition	Neutral	-7.4%	Scientific leadership roles changed, including retirement and discovery leadership promotion
Jun 30	Clinical enrollment completion	Positive	-0.5%	RISE3 pivotal epilepsy study completed enrollment with top-line results expected
Jun 29	Phase 3 trial initiation	Positive	-5.6%	BHV-1300 entered pivotal Phase 3 testing for Graves' disease
Jun 01	First-in-human dosing	Positive	+3.8%	BHV-8100 began human dosing with preliminary pharmacokinetic findings

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

BHVN's recent positive or informational announcements were followed by negative 24-hour reactions in four of five events, with one positive clinical event followed by a positive reaction.

Key Terms

trade secret misappropriation, targeted protein degradation, extracellular proteins

3 terms

trade secret misappropriation regulatory

"The jury found that Avilar and RA Capital willfully and maliciously misappropriated"

Trade secret misappropriation is the wrongful taking, use, or disclosure of a company’s confidential information—like formulas, processes, customer lists or business plans—without permission. For investors it matters because such theft can erase a company’s competitive edge, trigger costly lawsuits, disrupt revenue streams and damage reputation, similar to a rival obtaining and selling a firm’s secret recipe.

targeted protein degradation technical

"a Yale trade secret relating to its "MODA" targeted protein degradation platform"

Targeted protein degradation is a drug approach that uses small molecules to mark harmful or malfunctioning proteins inside cells so the cell’s own disposal system breaks them down, rather than simply blocking their activity. For investors, it matters because this method can potentially tackle diseases that traditional drugs cannot reach, offering a new class of therapies with broad commercial and patent potential—like switching from silencing a problem to removing it entirely.

extracellular proteins medical

"bind and eliminate disease-causing extracellular proteins from the body"

Proteins located outside cells in bodily fluids or the space between cells that carry out communication, structural support, immune defense, and signaling roles much like workers and messengers in a town square. They matter to investors because these proteins are common drug targets, diagnostic markers, and biologic product components; changes in their levels, function, or manufacturability can affect clinical trial outcomes, regulatory review, and market value of medical products and diagnostics.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW HAVEN, Conn., July 27, 2026 /PRNewswire/ -- Biohaven Ltd. and/or its wholly owned subsidiaries ("Biohaven") (NYSE: BHVN) and Yale University ("Yale") today announced that a federal jury in the U.S. District Court for the District of Delaware returned a verdict in their favor in the trade secret misappropriation and breach of contract litigation against Avilar Therapeutics, Inc. ("Avilar") and RA Capital Management GP, LLC ("RA Capital").

The jury found that Avilar and RA Capital willfully and maliciously misappropriated a Yale trade secret relating to its "MODA" targeted protein degradation platform, and that RA Capital separately breached its 2019 confidentiality agreement with Yale. The jury awarded Yale and Biohaven a combined $4 million in damages — $2 million to Yale for RA Capital's breach of contract, and $1 million each to Yale and Biohaven for trade secret misappropriation.

"This verdict confirms what we have said since we filed this case: RA Capital and Avilar improperly used confidential information to advance a competing company, and the jury agreed that they did so willfully and maliciously," said Dr. Vlad Coric, Chief Executive Officer of Biohaven. "We are grateful to the jury for paying careful attention to the evidence and to our legal team for their extraordinary work at trial. Biohaven is appreciative for our continued partnership with academic institutions like Yale, and remains committed to our mission of discovering, developing, and commercializing life-changing therapies for people with debilitating diseases."

Karen Peart, Yale's Associate Vice President for Communications, added, "Dr. Spiegel's work is the product of years of novel and rigorous research on extracellular degraders at Yale and exemplifies the innovative scholarship Yale faculty have advanced for decades. Yale is committed to fostering an environment where groundbreaking discoveries can flourish, improving lives, driving economic growth, and strengthening America's competitiveness. Through collaborations with industry partners, the university helps ensure that promising discoveries can be translated efficiently into products and therapies that serve the public good. These relationships depend on trust, integrity, and respect for the legal obligations that enable universities and industry to work together to advance innovation."

Biohaven was represented by K&L Gates LLP and Morris James LLP. Susman Godfrey LLP and Farnan LLP represented Yale.  

Background of the Case

• Dr. David Spiegel, a professor at Yale, developed the MODA platform, a technology designed to bind and eliminate disease-causing extracellular proteins from the body, and presented it at Yale's Lifesciences Pitchfest in 2018.
• RA Capital, a healthcare-focused investment firm, subsequently entered into a confidentiality agreement with Yale in April 2019 to evaluate a potential investment in and partnership around the technology.
• Over the following months, Dr. Spiegel shared confidential and detailed technical information with RA Capital, and the parties negotiated the terms of a possible deal. Those negotiations ended without an agreement in August 2019.
• Biohaven and Yale alleged that RA Capital, together with Avilar Therapeutics, a company RA Capital helped establish later that year, used confidential information from those discussions to build a competing drug development program instead of pursuing a partnership with Yale.
• Biohaven licensed the MODA platform from Yale to develop and commercialize the technology.
• Biohaven and Yale filed suit against Avilar and RA Capital in March 2023 in the U.S. District Court for the District of Delaware, alleging trade secret misappropriation and breach of the confidentiality agreement between Yale and RA Capital. The case proceeded to a jury trial beginning July 20, 2026 and the jury returned its verdict on July 24, 2026.

About Biohaven

Biohaven Ltd. (NYSE: BHVN) is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing therapies for people with debilitating diseases, with a broad pipeline spanning neuroscience, immunology, and other therapeutic areas. For more information, visit biohaven.com.

Forward-Looking Statements

This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "continue", "plan", "will", "believe", "may", "expect", "potentially", "potentially groundbreaking" and similar expressions, is intended to identify forward-looking statements. Investors are cautioned that any forward-looking statements, including statements regarding the future development, timing and potential marketing approval and commercialization of development candidates, are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors including: the expected timing, commencement and outcomes of Biohaven's planned and ongoing clinical trials; the timing of planned interactions and filings with the FDA; the timing and outcome of expected regulatory filings; complying with applicable US regulatory requirements; the potential commercialization of Biohaven's product candidates; and the effectiveness and safety of Biohaven's product candidates. Additional important factors to be considered in connection with forward-looking statements are described in Biohaven's filings with the Securities and Exchange Commission, including within the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". The forward-looking statements are made as of the date of this news release, and Biohaven does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor Contact:
Jennifer Porcelli
Vice President, Investor Relations, Biohaven
jennifer.porcelli@biohavenpharma.com
+1 (201) 248-0741

Media Contact:
Renée Soto
Founding Partner, Reevemark
renee.soto@reevemark.com
+1(212) 433-4606

View original content to download multimedia:https://www.prnewswire.com/news-releases/federal-jury-finds-avilar-therapeutics-and-ra-capital-willfully-and-maliciously-misappropriated-trade-secret-developed-at-yale-awards-biohaven-and-yale-university-4-million-302834812.html

SOURCE Biohaven Ltd.

FAQ

What did the July 2026 jury verdict award Biohaven (NYSE: BHVN) and Yale University?

The jury awarded a total of $4 million to Yale and Biohaven. According to Biohaven, Yale receives $2 million for RA Capital’s contract breach, plus $1 million for trade secret misappropriation, while Biohaven receives $1 million for misappropriation.

What did the jury find Avilar Therapeutics and RA Capital did in the Biohaven (BHVN) case?

The jury found Avilar and RA Capital willfully and maliciously misappropriated a Yale trade secret. According to Biohaven, the misappropriated secret related to Yale’s MODA targeted protein degradation platform, and RA Capital also breached its 2019 confidentiality agreement with Yale.

What is the MODA targeted protein degradation platform at the center of the BHVN lawsuit?

The MODA platform is a Yale-developed technology designed to bind and eliminate disease-causing extracellular proteins. According to Biohaven, Dr. David Spiegel created MODA, and Biohaven licensed the platform from Yale to develop and commercialize therapies based on this targeted protein degradation approach.

When did Biohaven (NYSE: BHVN) and Yale file their lawsuit against Avilar and RA Capital?

Biohaven and Yale filed the lawsuit in March 2023 in the U.S. District Court for the District of Delaware. According to Biohaven, the case alleged trade secret misappropriation and breach of a 2019 confidentiality agreement between Yale and RA Capital.

When was the trial held in the Biohaven and Yale versus Avilar and RA Capital case?

The jury trial began on July 20, 2026, and the verdict was returned on July 24, 2026. According to Biohaven, the trial took place in the U.S. District Court for the District of Delaware and focused on trade secret and contract claims.

How might the jury verdict affect Biohaven’s rights to the MODA platform (BHVN)?

The verdict confirms a jury finding that Yale’s MODA platform trade secret was misappropriated, with damages awarded to Yale and Biohaven. According to Biohaven, it has licensed the MODA platform from Yale for development and commercialization of therapies.